Financial Data and Key Metrics Changes - Sales in Q4 were $1.1 billion, representing an increase of 5% in local currency or 4% excluding acquisitions, and an 8% increase on a reported basis in US dollars [7] - Adjusted EPS for the quarter was $13.36, an 8% increase over the prior year, while reported EPS was $13.98 compared to $11.96 in the prior year [10][11] - Gross margin was 59.8%, a decrease of 140 basis points, impacted by unfavorable foreign currency and incremental gross tariff costs [8][9] - Adjusted operating profit amounted to $363 million, up 3% versus the prior year, with an adjusted operating margin of 32.1%, a decrease of 160 basis points [9][11] Business Line Data and Key Metrics Changes - Laboratory sales increased 3% in Q4, while industrial sales increased 7%, including a 3% benefit from acquisitions [7][8] - Food retail sales grew 19% in the quarter, and service revenue grew 8%, including a 2% benefit from acquisitions [8] - For the full year, local currency sales increased 3%, with adjusted operating profit declining 1% and adjusted EPS increasing 4% [11][12] Market Data and Key Metrics Changes - Local currency sales in the Americas increased 7%, Europe increased 4%, and Asia (rest of the world) also increased 4% [7] - Local currency sales in China increased 3% during the quarter, with modest growth expected in the lab and industrial segments [24][25] - Emerging markets outside of China accounted for 18% of sales in 2025 and grew above the company average due to dedicated resources and growth initiatives [25] Company Strategy and Development Direction - The company is focused on driving growth through the Spinnaker sales and marketing program and innovative product portfolio, capitalizing on automation, digitalization, and onshoring investments [6][19] - The company aims to maintain a strong culture of innovation and operational excellence to gain market share and deliver strong financial performance [6][26] - Future growth opportunities are anticipated from customer replacement cycles and investments in on- and nearshoring activities [26] Management's Comments on Operating Environment and Future Outlook - Management noted that while there have been favorable headlines in the pharma and life sciences markets, customers are expected to be cautious with investments at the start of the year [31][32] - The company does not anticipate significant improvement in market conditions in 2026 compared to the previous year, but remains confident in executing growth and productivity initiatives [14][15] - Management highlighted the importance of their innovative portfolio and strong global leadership positions in navigating ongoing market challenges [26] Other Important Information - Free cash flow for 2025 was $878 million, with a conversion ratio of 99% of adjusted net income [12] - Guidance for 2026 includes local currency sales growth forecast of approximately 4%, with adjusted EPS expected to be in the range of $46.05-$46.70, representing a growth rate of 8%-9% [15][18] Q&A Session Summary Question: Customer caution in pharma and life sciences - Management acknowledged that despite positive headlines, there is still uncertainty in the market leading to longer deal cycles and a cautious start to the year [31][32] Question: Components of guidance for pricing and volume - Management indicated that pricing is expected to start the year stronger due to mid-year pricing actions from the previous year, with a forecast of 3.5% for Q1 and 2.5% for the full year [34][35] Question: Growth in food retail - Management noted that food retail is a lumpy business with project-based revenue, and while they are pleased with Q4 performance, they expect flat growth for the full year 2026 due to tough comparisons [55][56] Question: Outlook for China and pharmacopoeia opportunity - Management stated that while there is good engagement in China, the pharmacopoeia opportunity will support ongoing growth but is not expected to result in a significant step change [57][75] Question: Reshoring and onshoring opportunities - Management views reshoring as a longer-term opportunity, likely materializing in 2027 and beyond, as factories need to be built before orders can be realized [61][62] Question: Performance in Europe - Management highlighted strong performance in Europe despite a softer economy, driven by effective sales strategies and innovation in product offerings [66][68] Question: Service business outlook - Management expects mid- to high-single-digit growth for the service business in 2026, with continued focus on penetrating the serviceable addressable market [70][71]

Financial Data and Key Metrics Changes - Sales in Q4 2025 were $1.1 billion, representing an 8% increase on a reported basis and a 5% increase in local currency, or 4% excluding acquisitions [6][10] - Adjusted EPS for the quarter was $13.36, an 8% increase over the prior year, while reported EPS was $13.98 compared to $11.96 in the prior year [9][10] - Gross margin was 59.8%, a decrease of 140 basis points, impacted by unfavorable foreign currency and tariff costs [7][11] Business Line Data and Key Metrics Changes - Laboratory sales increased 3%, industrial sales increased 7% (including a 3% benefit from acquisitions), and food retail sales grew 19% in the quarter [6][7] - Service revenue grew 8% in the quarter, including a 2% benefit from acquisitions [7] - For the full year 2025, local currency sales increased 3%, with adjusted operating profit declining 1% and adjusted EPS increasing 4% [10][11] Market Data and Key Metrics Changes - Local currency sales in the Americas increased 7%, Europe increased 4%, and Asia (rest of the world) increased 4% [6] - Local currency sales in China increased 3% during the quarter, with modest growth expected in 2026 [6][23] - Emerging markets outside of China accounted for 18% of sales in 2025 and grew above the company average [23] Company Strategy and Development Direction - The company is focused on driving growth through its Spinnaker sales and marketing program and innovative product portfolio, capitalizing on automation, digitalization, and onshoring investments [5][24] - The company aims to maintain a strong culture of innovation and operational excellence to gain market share and deliver strong financial performance [5][24] - Future growth opportunities are anticipated from customer replacement cycles and investments in on- and nearshoring activities [24] Management's Comments on Operating Environment and Future Outlook - Management noted that customers are expected to be cautious with investments at the start of the year due to ongoing geopolitical tensions and market uncertainties [12][28] - The company does not anticipate significant improvement in market conditions in 2026 compared to the previous year, but remains confident in its growth and productivity initiatives [12][13] - Management highlighted the importance of their innovative portfolio and strong global leadership positions in navigating market challenges [24] Other Important Information - Adjusted free cash flow for 2025 was $878 million, with a conversion ratio of 99% of adjusted net income [11] - Guidance for 2026 includes local currency sales growth of approximately 4%, adjusted EPS forecasted to be in the range of $46.05-$46.70, representing an 8%-9% growth rate [13][15] Q&A Session Summary Question: Customer caution in pharma and life sciences - Management acknowledged that while headlines have improved, there is still uncertainty leading to longer deal cycles, and customers are expected to start the year cautiously [28][30] Question: Components of guidance regarding pricing and volume - Management indicated that pricing is expected to start strong due to mid-year pricing actions from the previous year, with a forecast of 3.5% for Q1 and 2.5% for the full year [32][33] Question: Q1 guidance and market assumptions - Management provided insights into expected growth rates across different business lines, indicating a cautious outlook for Q1 compared to Q4 [40][41] Question: Food retail performance and outlook - Management noted that food retail is a lumpy business with project-based revenue, guiding for flat growth in 2026 after strong performance in 2025 [54][55] Question: China market and pharmacopoeia opportunity - Management expressed optimism about the ongoing growth in China, particularly in the pharmaceutical sector, but noted that significant changes are not expected immediately [56][74] Question: Reshoring and onshoring opportunities - Management sees reshoring as a longer-term opportunity, primarily beyond 2026, as factories need to be built before significant orders can be expected [60][62]